Literature DB >> 9109619

Food restriction reduces sympathetic support of blood pressure in spontaneously hypertensive rats.

J M Overton1, J M VanNess, R M Casto.   

Abstract

We tested the hypothesis that food restriction would attenuate the development of hypertension in spontaneously hypertensive rats (SHR). Furthermore, we hypothesized that food restriction would reduce the tonic sympathetic nervous system support of blood pressure in the SHR. Male SHR (Charles River, age 5 wk) were randomly assigned to ad libitum (ADLIB, n = 8) or food-restricted (FR, n = 9) groups. ADLIB rats were given free access to nonpurified diet and demineralized water. Food-restricted rats ate 60% of the amount of nonpurified diet consumed by rats in the ADLIB group. After 8 wk of treatment, ADLIB rats were heavier than FR rats (ADLIB = 318 +/- 4 g; FR = 193 +/- 5 g, P < 0.05). Blood pressure and heart rate (HR) were measured after chronic implantation of iliac arterial and jugular venous catheters. Food-restricted rats had lower mean arterial blood pressure (MAP) than ADLIB rats, measured in conscious, unrestrained state 4-6 h after catheterization (ADLIB = 162 +/- 3 mmHg; FR = 142 +/- 3 mmHg, P < 0.05) and measured on the day after surgery (ADLIB = 150 +/- 6 mmHg; FR = 130 +/- 3 mmHg, P < 0.05). There were no significant differences in resting HR on either day. Food-restricted rats exhibited augmented cardiac baroreflex-mediated bradycardia (bolus phenylephrine, 0.5-4.0 pg/kg intravenously) as assessed by linear slope of the AHR/AMAP relationship (ADLIB = -0.73 beats/(min x mmHg); FR = -1.62 beats/(min x mmHg), P < 0.05). Sympathetic support of blood pressure quantified by the depressor response to ganglionic blockade (hexamethonium 30 mg/kg; atropine 0.1 mg/kg intravenously), was greater in the ADLIB group (ADLIB: -59 +/- 8 mmHg; FR: -36 +/- 2 mmHg, P < 0.05). The results support the hypotheses that chronic food restriction reduces the development of hypertension and sympathetic support of MAP in spontaneously hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109619     DOI: 10.1093/jn/127.4.655

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  6 in total

Review 1.  Age-related cardiovascular disease and the beneficial effects of calorie restriction.

Authors:  Miranda M Y Sung; Jason R B Dyck
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Caloric restriction and heart function: is there a sensible link?

Authors:  Xuefeng Han; Jun Ren
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  Fasting-induced reductions in cardiovascular and metabolic variables occur sooner in obese versus lean mice.

Authors:  Jason M Tanner; Devin T Kearns; Bum Jun Kim; Crystal Sloan; Zhanjun Jia; Tianxin Yang; E Dale Abel; J David Symons
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

4.  Long-Term Caloric Restriction Improves Cardiac Function, Remodeling, Adrenergic Responsiveness, and Sympathetic Innervation in a Model of Postischemic Heart Failure.

Authors:  Claudio de Lucia; Giuseppina Gambino; Laura Petraglia; Andrea Elia; Klara Komici; Grazia Daniela Femminella; Maria Loreta D'Amico; Roberto Formisano; Giulia Borghetti; Daniela Liccardo; Maria Nolano; Steven R Houser; Dario Leosco; Nicola Ferrara; Walter J Koch; Giuseppe Rengo
Journal:  Circ Heart Fail       Date:  2018-03       Impact factor: 8.790

5.  Pathophysiological role of leptin in obesity-related hypertension.

Authors:  M Aizawa-Abe; Y Ogawa; H Masuzaki; K Ebihara; N Satoh; H Iwai; N Matsuoka; T Hayashi; K Hosoda; G Inoue; Y Yoshimasa; K Nakao
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.

Authors:  Mingge Ding; Jingyi Lei; Yinxian Qu; Huan Zhang; Weichuan Xin; Feng Ma; Shuwen Liu; Zhichao Li; Faguang Jin; Enqing Fu
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.